imatinib


Also found in: Medical, Wikipedia.

i·mat·i·nib

 (ĭ-măt′ə-nĭb)
n.
A tyrosine kinase inhibitor, C29H31N7O, used in its mesylate form to treat certain types of leukemia and various other diseases.
References in periodicals archive ?
The results showed that co-administration of guggulsterone resulted in a significant increase in chemo-sensitivity of K562/IMA cells to imatinib, compared with imatinib treatment alone.
Researchers from University College London (UCL) found that imatinib, a drug used to treat leukaemia, inhibited angiogenesis--the growth of abnormal blood vessels.
These advances led to the development of molecular targeted therapy for adjuvant and neoadjuvant protocols, using tyrosine kinase inhibitors like imatinib mesylate.
Key Words: Chronic myeloid leukemia, Tyrosine kinase inhibitor, Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib
Scientists achieved this in female mice by adding a currently approved chemotherapy drug, imatinib mesylate, to another chemotherapy drug cisplatin.
On the other hand, some manufacturers of generic imatinib listed on the stock market have gained ground on the Bombay Stock Exchange, which allows you to make a fairly accurate estimate of what the companies in pole position to win market share that Glivec "designer" is intended to give in the coming months.
Novartis filed suit against the law in 2006, in order to gain greater patent protection for a mesylate salt form of its cancer drug, imatinib (branded as Gleevec), but lost the initial case in an Indian High Court.
Patients with this mutation respond dramatically to the tyrosine kinase inhibitor, imatinib mesylate, with clinical, hematological and molecular remission.
After identification of activating mutations in the coding sequence of KIT as the pathogenetic mechanism underlying most GISTs, (2) and the concurrent availability of the ABL/KIT/PDGFR kinase inhibitor imatinib mesylate in early clinical trials for chronic myelogenous leukemia, (3) Joensuu et al (4) demonstrated for the first time the activity of this compound in a solid tumor.
Chronic myeloid leukaemia treatment has been revolutionised by the development of the tyrosine kinase inhibitor (TKI) Imatinib (STI571, Glivec[R]), which has demonstrated significant clinical efficacy in this type of cancer.
The current standard of care is surgery for localized cases, and adjuvant imatinib is recommended for tumors with a high risk of recurrence.